Unitary patents are important for the biopharma sector, but might be even more crucial for medtech.
Generic versions of Glaxosmithkline's Advair have been delayed again, but doubts about the group's HIV doublets are creeping in.
Biogen might be wondering what else it could have spent $1.2bn on as Forward Pharma's patent challenge against Tecfidera falters.
Regeneron and Sanofi's PCSK9 court win could reverberate across the whole monoclonal antibody space.
Earlier-than-expected US approval for Mylan's generic version of Teva's Copaxone is a blow to the struggling Israeli firm.
The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.
After a long internal battle Immunomedics has got out of a deal with Seattle Genetics.
The US regulator has come down surprisingly hard on biotech stock promotion schemes.
Acorda and Forward have been bashed by unfavourable US patent verdicts in multiple sclerosis, while Steadymed got a boost.